New developments in vaccines against respiratory viruses

Current Opinion in Investigational Drugs

Volumn 9, Issue 8, 2008, Pages 846-855

  Wroblewska, M ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

DNA vaccine; Live attenuated vaccine; Respiratory virus; Subunit vaccine; Vaccine; Viral vector

Indexed keywords

AVIAN INFLUENZA VACCINE; DNA VACCINE; INFLUENZA VACCINE; LIVE VACCINE; PALIVIZUMAB; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; VIRUS VACCINE; VIRUS VECTOR;

ADENOVIRUS; CORONAVIRUS; DNA MODIFICATION; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INFLUENZA VIRUS A; MASTADENOVIRUS; METAPNEUMOVIRUS; PARAINFLUENZA VIRUS; PARAMYXOVIRUS; PNEUMOVIRINAE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY VIRUS; REVIEW; RHINOVIRUS; SARS CORONAVIRUS;

ANIMALS; DISEASE OUTBREAKS; DNA VIRUS INFECTIONS; HUMANS; RESPIRATORY TRACT INFECTIONS; RNA VIRUS INFECTIONS; VIRAL VACCINES;

EID: 48349083415     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Gillim-Ross L, Subbarao K: Emerging respiratory viruses: Challenges and vaccine strategies. Clin Microbiol Rev (2006) 19(4):614-636. •• A comprehensive, updated review extensively covering newly recognized respiratory viruses, such as avian influenza viruses and the severe acute respiratory syndrome coronavirus, with special emphasis on vaccine strategies, immune correlates of protection and the outcomes of preclinical studies and clinical trials.
2. Schmidt AC: Progress in respiratory virus vaccine development. Semin Respir Crit Care Med (2007) 28(2):243-252.
3. Subbarao K, Katz JM: Influenza vaccines by reverse genetics. Curr Top Microbiol Immunol (2004) 283:313-342.
4. Walpita P, Flick R: Reverse genetics of negative-stranded RNA viruses: A global perspective. FEMS Microbiol Lett (2005) 244(1):9-18.
5. Marsh GA, Tannock GA: The role of reverse genetics in the development of vaccines against respiratory viruses. Exp Opin Biol Ther (2005) 5(3):369-380.
6. Palese P: Making better influenza virus vaccines? Emerg Infect Dis (2006) 12(1):61-65.
7. Carrat F, Flahault A: Influenza vaccine: The challenge of antigenic drift. Vaccine (2007) 25(39-40):6852-6862. • A detailed review of the genetic variability of influenza viruses, with special emphasis on the rationale behind developing a universal vaccine which would be broadly cross-protective against different influenza virus strains.
8. Johansson BE, Brett IC: Changing perspective on immunization against influenza. Vaccine (2007) 25(16):3062-3065.
9. Influenza vaccines. Wkly Epidemiol Rec (2005) 80(33):279-287.
10. Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solorzano A, Swayne DE, Cox NJ, Katz JM, Taubenberger JK, Palese P, Garcia-Sastre A: Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science (2005) 310(5745):77-80.
11. State of the art of new vaccines: Research and development. WHO Initiative for Vaccine Research, Geneva, Switzerland (2006). http://www.who.int/vaccines-documents/DocsPDF06/814.pdf
12. Fiore AE, Shay DK, Haber P, Iskander JK, Uyeki TM, Mootrey G, Bresee JS, Cox NJ: Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR Recomm Rep (2007) 56(RR-6):1-54.
13. Treanor JD: Influenza - the goal of control. N Eng J Med (2007) 357(14):1439-1441.
14. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E: Effectiveness of influenza vaccine in the community-dwelling elderly. N Eng J Med (2007) 357(14):1373-1381. • A recently published study (October 2007), comprising over 700,000 person-seasons of observations during ten influenza seasons. The authors concluded that influenza vaccination of community-dwelling elderly people was associated with significant reductions in the risk of hospitalization for pneumonia or influenza and in the risk of death.
15. Couch RB, Winokur P, Brady R, Belshe R, Chen WH, Cate TR, Sigurdardottir B, Hoeper A, Graham IL, Edelman R, He F et al: Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine (2007) 25(44):7656-7663.
16. Bardiya N, Bae JH: Influenza vaccines: Recent advances in production technologies. Appl Microbiol Biotechnol (2005) 67(3):299-305.
17. Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, Holden-Wiltse J, Liang H, Gilbert A, Cox M: Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: A randomized controlled trial. J Am Med Assoc (2007) 297(14):1577-1582.
18. Ozaki H, Govorkova EA, Li C, Xiong X, Webster RG, Webby RJ: Generation of high-yielding influenza A viruses in African green monkey kidney (Vero) cells by reverse genetics. J Virol (2004) 78(4):1851-1857.
19. Kistner O, Howard MK, Spruth M, Wodal W, Bruhl P, Gerencer M, Crowe BA, Savidis-Dacho H, Livey I, Reiter M, Mayerhofer I et al: Cell-culture (Vero)-derived whole virus (H5N1) vaccine based on wild type virus strain induces cross-protective immune responses. Vaccine (2007) 25(32):6028-6036. • This study describes an important strategy to improve the yield of influenza vaccine by growing the virus in a cell culture system, as opposed to embryonated eggs. This would allow a rapid production of a pandemic vaccine, should it be needed. Cell culture-grown H5N1 virus vaccines induced cross-reacting antibodies and highly cross-reactive T-cell responses, as well as protection in a mouse challenge model.
20. Rappuoli R: Cell-culture-based vaccine production: Technological options. The Bridge. National Academy of Engineering (2006) 36(3):25-30.
21. Novartis International AG: Novartis gains European approval for its innovative flu vaccine Optaflu. Press release (2007):13 June.
22. Committee for medicinal products for human use plenary meeting monthly report. European Medicines Agency, London, UK (2007). http://www.emea. europa.eu
23. Garmise RJ, Staats HF, Hickey AJ: Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS PharmSciTech (2007) 8(4):2-10.
24. Ulmer JB: Novel vaccines: Bridging research, development and production - CHI's inaugural conference. IDrugs (2006) 9(10):696-698.
25. Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ: Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine (2006) 24(21):4475-4481.
26. Zuccotti G, Amendola A, Vigano A, Pariani E, Zappa A, Pogliani L, Giacomet V, Savarino A, Podesta A, Rottoli A, Tanzi E et al: Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma. Vaccine (2007) 25(37-38):6692-6698.
27. Gerhard W, Mozdzanowska K, Zharikova D: Prospects for universal influenza virus vaccine. Emerg Infect Dis (2006) 12(4):569- 574.
28. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W: A 'universal' human influenza A vaccine. Virus Res (2004) 103(1-2):173-176.
29. Tompkins SM, Zhao Z-S, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL: Matrix protein 2 vaccination and protection against influenza viruses, including H5N1. Emerg Infect Dis (2007) 13(3):426-435.
30. Keiser J: A one-size-fits-all flu vaccine? Science (2006) 312(5772):380-382.
31. Bianchi E, Liang X, Ingallinella P, Finotto M, Chastain MA, Fan J, Fu T-M, Song HC, Horton MS, Freed DC, Manger W et al: Universal influenza B vaccine based on the maturational cleavage site of the haemagglutinin precursor. Virology (2005) 79(12):7380-7388.
32. Coulter A, Harris R, Davis R, Drane D, Cox J, Ryan D, Sutton P, Rockman S, Pearse M: Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine (2003) 21(9-10):946-949.
33. Cumulative number of confirmed human cases of avian influenza A/(H5N1) reported to WHO. WHO, Geneva, Switzerland, (2007). http://www.who.int/ csr/disease/avian_influenza/country/cases_table_2007_10_17/en/index.html
34. Yang Y, Halloran ME, Sugimoto JD, Longini IM Jr: Detecting human-to-human transmission of avian influenza A (H5N1). Emerg Infect Dis (2007) 13(9):1348-1352.
35. Haque A, Hober D, Kasper LH: Confronting potential influenza A (H5N1) pandemic with better vaccines. Emerg Infect Dis (2007) 13(10):1512-1518.
36. Subbarao K, Luke C: H5N1 viruses and vaccines. PLoS Pathog (2007) 3(3):e40.
37. Hatta M, Hatta Y, Kim JH, Watanabe S, Shinya K, Nguyen T, Lien PS, Le QM, Kawaoka Y: Growth of H5N1 influenza A viruses in the upper respiratory tracts of mice. PLoS Pathog (2007) 3(10):e133. •• Based on data from a mouse model, the authors suggest that Lys at position 627 of PB2 (polymerase) confers the advantage of efficient growth in the respiratory tracts of mammals to avian influenza H5N1 viruses. This could be the pathomechanism underlying possible person-to-person transmission of the virus, which may result in a pandemic with an extremely high mortality rate.
38. Conenello GM, Zamarin D, Perrone LA, Tumpey T, Palese P: A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog (2007) 3(10):e141. • An interesting paper on the possible pathomechanism behind the very high lethality of the 1918 pandemic strain of the influenza A H1N1 virus. The authors claim that a single mutation in the PB1-F2 of H5N1 (HK/97) and the 1918 strain of influenza A virus contributed to increased virulence of these strains.
39. Sambhara S, Poland GA: Breaking the immunogenicity barrier of bird flu vaccines. Lancet (2007) 370:544-545.
40. Poland GA: Vaccines against avian influenza - a race against time. N Engl J Med (2006) 354(13):1411-1413.
41. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, Devaster J-M, Leroux-Roels G: Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet (2007) 370(9587):580-589. • A study investigating the improvement of immunogenicity and the spectrum of activity of a pandemic avian influenza H5N1 vaccine. A randomized controlled trial showed that a recombinant H5N1 split-virion vaccine was safe in volunteers between the ages of 18 and 60. The adjuvanted formulation of the vaccine conferred significant antigen sparing, which could contribute to an increased production capacity in the face of a pandemic. Cross-clade antibody responses were recorded.
42. McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA: Reduced sensitivity of influenza A (H5N1) to oseltamivir. Emerg Infect Dis (2007) 13(9):1354-1357.
43. Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M: Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Eng J Med (2006) 354(13):1343-1351.
44. Influenza virus vaccine H5N1. Product approval information - licensing action. FDA, Rockville, MD, USA (2007). http://www.fda.gov/cber/ approvltr/h5n1san041707L.htm
45. Sinovac Biotech Ltd: Sinovac receives China State Food and Drug Administration (SFDA) approval for pandemic influenza H5N1 vaccine. Press release (2008): April 02.
46. Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HKB, Graham IL, Noah DL, He F, Hill H: Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis (2008) 197(5):667-675.
47. 4th WHO meeting on evaluation of pandemic influenza prototype vaccines in clinical trials, 14-15 February 2008, WHO HQ, Geneva. WHO, Geneva, Switzerland (2008). http://www.who.int/vaccine_research/diseases/influenza/ meeting_140208/en/index.html
48. Suguitan AL Jr, McAuliffe J, Mills KL, Jin H, Duke G, Lu B, Luke CJ, Murphy B, Swayne DE, Kemble G, Subbarao K: Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PloS Med (2006) 3(9):e360.
49. NIAID DNA vaccine for H5N1 avian influenza enters human trial. NIAID, Bethesda, MD, USA (2007). http://www3.niaid.nih.gov/news/newsreleases/ 2007/FluDNAVax.htm
50. El Sahly HM, Keitel WA: Pandemic H5N1 influenza vaccine development: An update. Expert Rev Vaccines (2008) 7(2):241-247.
51. 3rd WHO meeting on evaluation of pandemic influenza prototype vaccines in clinical trials, 15-16 February, WHO HQ, Geneva. WHO, Geneva, Switzerland (2007). http://www.who.int/vaccine_research/diseases/influenza/ meeting_150207/en/index1.html
52. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau NVV, Hien TT, Sallusto F, Ha DQ, Farrar J, de Jong MD et al: Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med (2007) 4(5):e178.
53. Goudsmit J: Discovery of a unique set of human monoclonal antibodies active against H5N1. Ability to cure disease and provide immediate protection against infection. 5th International Bird Flu Summit, Las Vegas, USA (2007). http://hugin.info/132631/R/1156548/223246.pdf
54. Atmar RL, Keitel WA, Patel SM, Katz JM, She D, El Sahly H, Pompey J, Cate TR, Couch RB: Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis (2006) 43(9):1135-1142.
55. Chen H, Matsuoka Y, Swayne D, Chen Q, Cox NJ, Murphy BR, Subbarao K: Generation and characterization of a cold-adapted influenza A H9N2 re-assortant as a live pandemic influenza virus vaccine candidate. Vaccine (2003) 21(27-30):4430-4436.
56. Luke CJ, Subbarao K: Vaccines for pandemic influenza. Emerg Infect Dis (2006) 12(1):66-72.
57. Belshe RB, Karron RA, Newman FK, Anderson EL, Nugent SL, Steinhoff M, Clements ML, Wilson MH, Hall SL, Tierney EL, Murphy BR: Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children. J Clin Microbiol (1992) 30(8):2064-2070.
58. Durbin AP, Karron RA: Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines. Clin Infect Dis (2003) 37(12):1668-1677.
59. Cortez KJ, Erdman DD, Peret TC, Gill VJ, Childs R, Barrett AJ, Bennett JE: Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population. J Infect Dis (2001) 184(9):1093-1097.
60. Henrickson KJ: Parainfluenza viruses. Clin Microbiol Rev (2003) 16(2):242-264.
61. Belshe RB, Newman FK, Anderson EL, Wright PF, Karron RA, Toleffson S, Henderson FW, Meissner HC, Madhi S, Roberton D, Marshall H et al: Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children. J Infect Dis (2004) 190(12):2096-2103.
62. Schmidt AC, McAuliffe JM, Murphy BR, Collins PL: Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol (2001) 75(10):4594-4603.
63. Nolan SM, Skiadopoulos MH, Bradley K, Kim OS, Bier S, Amaro-Carambot E, Surman SR, Davis S, St Claire M, Elkins R, Collins PL et al: Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3′ genomic promoter mutation and L-polymerase mutations are attenuated and protective in nonhuman primates. Vaccine (2007) 25(34):6409- 6422.
64. Falsey AR, Walsh EE: Respiratory syncytial virus infection in adults. Clin Microbiol Rev (2000) 13(3):371-384.
65. Englund J: In search of a vaccine for respiratory syncytial virus: The saga continues. J Infect Dis (2005) 191(7):1036-1039.
66. Sullender WM: Respiratory syncytial virus genetic and antigenic diversity. Clin Microbiol Rev (2000) 13(1):1-15.
67. Hussell T, Humphreys IR: Nasal vaccination induces protective immunity without immunopathology. Clin Exp Immunol (2002) 130(3):359-362.
68. Takimoto T, Hurwitz JL, Coleclough C, Prouser C, Krishnamurthy S, Zhan X, Boyd K, Scroggs RA, Brown B, Nagai Y, Portner A, Slobod KS: Recombinant Sendai virus expressing the G glycoprotein of respiratory syncytial virus (RSV) elicits immune protection against RSV. J Virol (2004) 78(11):6043-6047.
69. Brandenburg AH, Neijens HJ, Osterhaus ADME: Pathogenesis of RSV lower respiratory tract infection: Implications for vaccine development. Vaccine (2001) 19(20-22):2769-2782.
70. Openshaw PJM, Tregoning JS: Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev (2005) 18(3):541-555.
71. Wright PF, Karron RA, Belshe RB, Thompson J, Crowe JE Jr, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE et al: Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis (2000) 182(5):1331-1342.
72. Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, Polack FP, Randolph VB, Deatly A, Hackell J, Gruber W et al: Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis (2005) 191(7):1093-1104.
73. Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, O'Shea AF, Gruber WC, Murphy BR: The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial vaccines. Vaccine (2007) 25(42):7372-7378. • An interesting, much awaited report on the lack of enhanced lower respiratory tract disease in children vaccinated against HRSV, upon infection with a wild strain of the virus.
74. Kieny MP, Excler J-L, Girard M: Research and development of new vaccines against infectious diseases. Am J Public Health (2004) 94(11):1931-1935.
75. Piedra PA, Grace S, Jewell A, Spinelli S, Hogerman DA, Malinoski F, Hiatt PW: Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr Infect Dis J (1998) 17(3):217-224.
76. Tang RS, MacPhail M, Schickli JH, Kaur J, Robinson CL, Lawlor HA, Guzzetta JM, Spaete RR, Haller AA: Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J Virol (2004) 78(20):11198-11207.
77. Collins PL, Murphy BR: New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc (2005) 2(2):166-173.
78. MedImmune Inc: MedImmune's Synagis (palivizumab) approved for marketing by FDA; First monoclonal antibody for infectious disease. Press release (1998): June 19.
79. Kahn JS: Epidemiology of human metapneumovirus. Clin Microbiol Rev (2006) 19(3):546-557. •• An excellent review of human metapneumovirus epidemiology (including genetic diversity and phylogenetic analysis of HMPV, clinical manifestations, potential treatment and immunization).
80. Williams JV, Harris PA, Tollefson SJ, Halburnt-Rush LL, Pingsterhaus JM, Edwards KM, Wright PF, Crowe JE: Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med (2004) 350(5):443-450.
81. Geretti AM: The expanding role of common respiratory viruses in human disease. J Med Microbiol (2003) 52(Pt 6):443-445.
82. Louie JK, Schnurr DP, Pan C-Y, Carter C, Tougaw S, Ventura J, Norman A, Belmusto V, Rosenberg J, Trochet G: A summer outbreak of human metapneumovirus infection in a long-term-care facility. J Infect Dis (2007) 196(5):705-708.
83. van den Hoogen BG, Herfst S, Sprong L, Cane PA, Forleo-Neto E, de Swart RL, Osterhaus AD, Fouchier RA: Antigenic and genetic variability of human metapneumoviruses. Emerg Infect Dis (2004) 10(4):658-666.
84. Biacchesi S, Pham QN, Skiadopoulos MH, Murphy BR, Collins PL, Buchholz UJ: Infection of non-human primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. J Virol (2005) 79(19):12608-12613.
85. Herfst S, de Graaf M, Schrauwen EJA, Ulbrandt ND, Barnes AS, Senthil K, Osterhaus ADME, Fouchier RAM, van den Hoogen BG: Immunization of Syrian golden hamsters with F subunit vaccine of human metapneumovirus induces protection against challenge with homologous or heterologous strains. J Gen Virol (2007) 88(Pt 10):2702-2709.
86. Cseke G, Wright DW, Tollefson SJ, Johnson JE, Crowe JE Jr, Williams JV: Human metapneumovirus fusion protein vaccines that are immunogenic and protective in cotton rats. J Virol (2007) 81(2):698-707.
87. Tang RS, Mahmood K, MacPhail M, Guzzetta JM, Haller AA, Liu H, Kaur J, Lawlor HA, Stillman EA, Schickli JH, Fouchier RA et al: A host-range restricted parainfluenza virus type 3 (PIV3) expressing the human metapneumovirus (hMPV) fusion protein elicits protective immunity in African green monkeys. Vaccine (2005) 23(14):1657-1667.
88. Pham QN, Biacchesi S, Skiadopoulos MH, Murphy BR, Collins PL, Buchholz UJ: Chimeric recombinant human metapneumoviruses with the nucleoprotein or phosphoprotein open reading frame replaced by that of avian metapneumovirus exhibit improved growth in vitro and attenuation in vivo. J Virol (2005) 79(24):15114-15122.
89. Herd KA, Mahalingam S, Mackay IM, Nissen M, Sloots TP, Tindle RW: Cytotoxic T-lymphocyte epitope vaccination protects against human metapneumovirus infection and disease in mice. J Virol (2006) 80:2034-2044.
90. Williams JV, Chen Z, Cseke G, Wright DW, Keefer CJ, Tollefson SJ, Hessell A, Podsiad A, Shepherd BE, Sanna PP, Burton DR, Crowe JE Jr, Williamson RA: A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo. J Virol (2007) 81(15):8315- 8324.
91. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. WHO, Geneva, Switzerland (2008). http://www.who. int/csr/sars/country/table2004_04_21/en/index.html
92. Rizzo KA, Kuchar T, Chubet RG, Holtz KM, Zhou Z, Wang M, Post PL, Cox MMJ: Development of a SARS recombinant CoV-spike protein vaccine. ICAAC (2004): poster 277. http://www.proteinsciences.com/products/pdf/ ICAACPoster2004.pdf
93. Wu L-P, Wang N-C, Chang Y-H, Tian X-Y, Na D-Y, Zhang L-Y, Zheng L, Lan T, Wang L-F, Liang G-D: Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis (2007) 13(10):1562- 1564.
94. Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X, Hensley LE, Prabakaran P, Rockx B, Sidorov IA, Corti D et al: Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Nat Acad Sci USA (2007) 104(29):12123-12128.
95. Ghosh S, Champlin R, Couch R, Englund J, Raad I, Malik S, Luna M, Whimbey E: Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. Clin Infect Dis (1999) 29(3):528-532.
96. Perkins JC, Tucker DN, Knope HL, Wenzel RP, Hornick RB, Kapikian AZ, Chanock RM: Evidence for protective effect of an inactivated rhinovirus vaccine administered by the nasal route. Am J Epidemiol (1969) 90(4):319-326.
97. Stott EJ, Draper C, Stones PB, Tyrrell DA: Absence of heterologous antibody responses in human volunteers after rhinovirus vaccination. Arch Gesamte Virusforsch (1969) 28(1):89-92.
98. Francis MJ, Hastings GZ, Sangar DV, Clark RP, Syred A, Clarke BE, Rowlands DJ, Brown F: A synthetic peptide which elicits neutralizing antibody against human rhinovirus type 2. J Gen Virol (1987) 68(Pt 10):2687-2691.
99. Arnold GF, Resnick DA, Li Y, Zhang A, Smith AD, Geisler SC, Jacobo-Molina A, Lee W, Webster RG, Arnold E: Design and construction of rhinovirus chimeras incorporating immunogens from polio, influenza, and human immunodeficiency viruses. Virology (1994) 198(2):703-708.
100. Gray GC, Goswani PR, Malasig MD, Hawksworth AW, Trump DH, Ryan MA, Schnurr DP: Adult adenovirus infections: Loss of orphaned vaccines precipitates military respiratory disease epidemics. For the Adenovirus Surveillance Group. Clin Infect Dis (2000) 31(3):663-670.
101. Russell KL, Hawksworth AW, Ryan MA, Strickler J, Irvine M, Hansen CJ, Gray GC, Gaydos JC: Vaccine-preventable adenoviral respiratory illness in US military recruits, 1999-2004. Vaccine (2006) 24(15):2835-2842.
102. Adenovirus vaccine information paper. Military Infectious Diseases Research Program, Fort Detrick, MD, USA (2005). http://mrmc.amedd.army.mil/ docs/midrp/Vaccine_and_drug_info_papers.pdf
103. Jeon K, Kang CI, Yoon CH, Lee DJ, Kim CH, Chung YS, Kang C, Choi CM: High isolation rate of adenovirus serotype 7 from South Korean military recruits with mild acute respiratory disease. Eur J Clin Microbiol Infect Dis (2007) 26(7):481-483.
104. Vora GJ, Lin B, Gratwick K, Meador C, Hansen C, Tibbetts C, Stenger DA, Irvine M, Seto D, Purkayastha A, Freed NE et al: Co-infections of adenovirus species in previously vaccinated patients. Emerg Infect Dis (2006) 12(6):921-930.
105. Imler J-C: Adenovirus vectors as recombinant viral vaccines. Vaccine (1995) 13(13):1143-1151.
106. Barouch DH, Nabel GJ: Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther (2005) 16(2):149-156.
107. Arvin AM, Greenberg HB: New viral vaccines. Virology (2006) 344(1):240-249.
108. Olszewska W, Zambon M, Openshaw PJ: Development of vaccines against common colds. Br Med Bull (2002) 62:99-111